ATE258596T1 - Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen - Google Patents
Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmenInfo
- Publication number
- ATE258596T1 ATE258596T1 AT94922265T AT94922265T ATE258596T1 AT E258596 T1 ATE258596 T1 AT E258596T1 AT 94922265 T AT94922265 T AT 94922265T AT 94922265 T AT94922265 T AT 94922265T AT E258596 T1 ATE258596 T1 AT E258596T1
- Authority
- AT
- Austria
- Prior art keywords
- treating
- nucleic acid
- degeneration
- preventing
- pharmaceutical composition
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000027418 Wounds and injury Diseases 0.000 title abstract 2
- 230000030833 cell death Effects 0.000 title abstract 2
- 230000006378 damage Effects 0.000 title abstract 2
- 230000007850 degeneration Effects 0.000 title abstract 2
- 208000014674 injury Diseases 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 abstract 2
- 102100027584 Protein c-Fos Human genes 0.000 abstract 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 abstract 2
- 102100023132 Transcription factor Jun Human genes 0.000 abstract 2
- 230000000692 anti-sense effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 230000001364 causal effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93111059 | 1993-07-10 | ||
| PCT/EP1994/002218 WO1995002051A2 (en) | 1993-07-10 | 1994-07-06 | A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE258596T1 true ATE258596T1 (de) | 2004-02-15 |
Family
ID=8213060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94922265T ATE258596T1 (de) | 1993-07-10 | 1994-07-06 | Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7326783B2 (de) |
| EP (1) | EP0708829B8 (de) |
| JP (1) | JPH08512300A (de) |
| AT (1) | ATE258596T1 (de) |
| AU (1) | AU7345694A (de) |
| DE (1) | DE69433520T2 (de) |
| WO (1) | WO1995002051A2 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985558A (en) * | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US5985592A (en) * | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
| FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| EP1055366A1 (de) * | 1999-05-26 | 2000-11-29 | Boehringer Ingelheim International GmbH | Verwendung von transgenen mäusen mit fehlender expression von jun-b in myeloidzellen |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US20070270579A1 (en) * | 2001-05-18 | 2007-11-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20070042983A1 (en) * | 2001-05-18 | 2007-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20050282188A1 (en) * | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20060241075A1 (en) * | 2001-05-18 | 2006-10-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA) |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AUPS078002A0 (en) * | 2002-02-27 | 2002-03-21 | Unisearch Limited | Dnazyme therapeutics |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| DK1802749T3 (da) | 2004-10-21 | 2012-11-26 | Mayo Foundation | KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser |
| MX2007007184A (es) * | 2005-05-05 | 2008-01-14 | Antisense Pharma Gmbh | Uso de bajas dosis de oligonucleotidos antisentido para tgf-beta, vegf, interleucina-10, c-jun, c-fos o genes e2 de prostaglandina en el tratamiento de tumores. |
| US20090176725A1 (en) * | 2005-08-17 | 2009-07-09 | Sirna Therapeutics Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| CA2692287A1 (en) * | 2007-06-29 | 2009-01-08 | Newsouth Innovations Pty Limited | Treatment of rheumatoid arthritis |
| CN103068983A (zh) | 2010-06-11 | 2013-04-24 | 安提森斯制药有限公司 | 用于选择性寡核苷酸修饰的方法 |
| EP3327125B1 (de) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina) |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| WO2017138924A1 (en) | 2016-02-09 | 2017-08-17 | Autotelic Llc | Compositions and methods for treating pancreatic cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923901A (en) * | 1987-09-04 | 1990-05-08 | Millipore Corporation | Membranes with bound oligonucleotides and peptides |
| US5225326A (en) * | 1988-08-31 | 1993-07-06 | Research Development Foundation | One step in situ hybridization assay |
| US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
| WO1992015680A1 (en) | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
| US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| AU5005093A (en) | 1992-10-21 | 1994-05-09 | Temple University - Of The Commonwealth System Of Higher Education | Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer |
-
1994
- 1994-07-06 JP JP7503825A patent/JPH08512300A/ja active Pending
- 1994-07-06 AT AT94922265T patent/ATE258596T1/de active
- 1994-07-06 WO PCT/EP1994/002218 patent/WO1995002051A2/en active IP Right Grant
- 1994-07-06 EP EP94922265A patent/EP0708829B8/de not_active Expired - Lifetime
- 1994-07-06 US US08/591,486 patent/US7326783B2/en not_active Expired - Fee Related
- 1994-07-06 AU AU73456/94A patent/AU7345694A/en not_active Abandoned
- 1994-07-06 DE DE69433520T patent/DE69433520T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0708829B1 (de) | 2004-01-28 |
| DE69433520D1 (de) | 2004-03-04 |
| DE69433520T2 (de) | 2004-11-11 |
| US20020037866A1 (en) | 2002-03-28 |
| WO1995002051A2 (en) | 1995-01-19 |
| AU7345694A (en) | 1995-02-06 |
| JPH08512300A (ja) | 1996-12-24 |
| EP0708829B8 (de) | 2004-07-21 |
| EP0708829A1 (de) | 1996-05-01 |
| US7326783B2 (en) | 2008-02-05 |
| WO1995002051A3 (en) | 1995-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE258596T1 (de) | Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen | |
| NO930515L (no) | Oligonukleotider for modulering av effektene av cytomegalovirusinfeksjoner | |
| FI964792A (fi) | raf-geenin ilmentymisen muuttaminen antisense-oligonukleotideillä | |
| DK0788366T3 (da) | Anvendelse af 2'-substituerede oligonucleotider til regulering af genekspression | |
| DE69404835T2 (de) | Triesters von phosphorothioaten oligonukleotiden und verfahren zur herstellung | |
| NO973838L (no) | DNA-molekyler, deres fremstilling samt anvendelse ved genterapi | |
| ATE406453T1 (de) | Verfahren zür einführung und expression von genen in tierischen zellen | |
| FR2715847B1 (fr) | Composition contenant des acides nucléiques, préparation et utilisations. | |
| ATE156517T1 (de) | Antisens-oligonukleotide zur behandlung von krebs | |
| DE69403642T2 (de) | 7-deazapurin modifizierte oligonukleotide | |
| NO901213D0 (no) | Genetiske enheter for inhibering av funksjonen til rna. | |
| DE69620906D1 (de) | Antisense-oligonukleotidmodulation der raf-genexpression | |
| WO2001080840A3 (en) | Cytotoxic agents comprising single-stranded and/or looped dna | |
| KR940021073A (ko) | 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i | |
| DE68926455D1 (de) | Verfahren zur identifizierung von bakterien | |
| ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
| AU2180501A (en) | Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide | |
| DE69810906D1 (de) | Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock | |
| WO1993013204A3 (de) | Mittel zur stimulierung der teilungsaktivität tierischer zellen | |
| Prabhu | Identification of Phosphate Oxygens Important for the Self Cleavage Activity of Ribozyme G73 From the Hepatitis Delta Virus | |
| DE3875370D1 (de) | Verfahren zur behandlung von triptophanase enthaltenden mikroorganismuszellen oder deren behandelte produkte. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0708829 Country of ref document: EP |